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Glioblastoma (GBM) is one of the most fatal brain cancers with median survival of
only 14.6 months. Hence, more efficacious therapies are necessary. Ferrocifen
(FcTriOH) is an organometallic antitumor compound, selectively active on cancer
cells [1]. However, this metallocomplexe is highly insoluble in water, requiring a
formulation stage before being in vivo administered. Lipid nanocapsules (LNC),
prepared via a solvent free process of emulsion phase inversion, could be a suitable
vehicle for FcTriOH [2]. Moreover, NFL peptide is able to enter massively into
glioblastoma cells, and poorly in healthy neurons and astrocytes (NHA) [3]. Indeed,
the aim of the study was to evaluate the effect of the surface-functionalizing NFL
concentrations on LNC uptake in U87MG human GBM cells. Moreover, FcTriOH
was encapsulated in LNC and their in vitro efficacy on U87MG cells was evaluated.
Finally, in vivo antitumor effect was evaluated in ectopic and orthotopic murine
U87MG tumor models.
Fluorescent LNC (F1), LNC with 0.86% w/w and LNC with 2.58% w/w surface-
adsorbed NFL (F2 and F3 respectively) were prepared and characterized. FACS
analysis revealed that cellular uptake of F3 into U87MG cells was 31.5 and 1.6-folds
higher after 6 h compared to F1 and F2 respectively. Moreover, uptake of F3 was
significantly higher in the GBM cells compared to NHA, whereas F1 was
internalized preferentially in NHA. Uptake of F3 in U87MG cells was energy
dependent. Macropinocytosis was possibly the major uptake pathway, followed by
clathrin-dependent endocytosis.
Then, FcTriOH loaded LNCs have been successfully prepared with a drug loading of
2.4 % and an encapsulation efficacy of 99 %. MTS assay on U87MG cells revealed
an IC50 of 0.46 µM for F3-FcTriOH (free FcTriOH: IC50 = 1.31 µM).
Preliminary in vivo experiments on subcutaneous U87MG tumor bearing nude mice
showed significantly reduced relative tumor volume after two intravenous injections
of F1-FcTriOH and F3-FcTriOH compared to saline. Moreover, intracranial
administration of F3/F3-FcTriOH in orthotopic U87MG tumor bearing mice revealed
2 to 3-folds higher apparent diffusion coefficients (ADC) near the injection site in
diffusion tensor imaging, compared to F1/F1-FcTriOH. Although dose adjustment
will be necessary to avoid toxic effects, the results are promising as therapy
induced increased ADC values could indicate possible cell necrosis/lysis.
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